🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Cytokinetics clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our USA, UK and China registers with Cytokinetics as lead sponsor. Synced 26 Sep 2026
5Current trials
2Recruiting now
1Drug in these trials
3Trial registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Cytokinetics is the lead sponsor of 5 current clinical trials in our USA, UK and China registers. 2 are recruiting patients now. The most common phase is Phase 2/3. The drugs named most often in its trials are Aficamten. The most-studied condition is Pediatric.

ClinicalTrials.gov trials by status

  • Recruiting240%
  • Active, closed240%
  • By invitation120%

Trials by phase

  • Phase 2/3240%
  • Phase 3240%
  • Phase 2120%
01

Clinical trials sponsored by Cytokinetics

5 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
NCT06736574 · ClinicalTrials.gov ↗ · Heart Failure, Heart Failure With Reduced Ejection Fraction
Phase 3 Recruiting 2024-12 UK, USA, China
AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF
NCT06793371 · ClinicalTrials.gov ↗ · Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF)
Phase 2 Recruiting 2025-02 USA
Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM
NCT04848506 · ClinicalTrials.gov ↗ · Symptomatic Hypertrophic Cardiomyopathy (HCM)
Drug: Aficamten
Phase 2/3 By invitation 2021-05 UK, USA
A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).
NCT06412666 · Pediatric, Symptomatic Obstructive Hypertrophic Cardiomyopathy
Drug: Aficamten
Phase 2/3 Active, closed 2024-05 UK, USA
A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)
NCT06081894 · ClinicalTrials.gov ↗ · Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
Drug: Aficamten
Phase 3 Active, closed 2023-08 UK, USA, China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Cytokinetics trials

1 compound

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Cytokinetics trials

7 conditions
Pediatric1Symptomatic Obstructive Hypertrophic Cardiomyopathy1Heart Failure1Heart Failure With Reduced Ejection Fraction1Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy1Symptomatic Hypertrophic Cardiomyopathy (HCM)1Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF)1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in USA52
Clinical trials in UK41
Clinical trials in China21

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Pediatric

SponsorTrials
BioCryst Pharmaceuticals1

Sponsors with the most current trials registered for this condition.

06

Questions about Cytokinetics trials

How many clinical trials does Cytokinetics sponsor?

Cytokinetics is the lead sponsor of 5 current trials on ClinicalTrials.gov in our USA, UK and China registers, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Cytokinetics trials recruiting?

Yes. 2 of its 5 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Cytokinetics testing?

Its current trials name 1 drug or biological as interventions. The most frequent are Aficamten (3). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.